Tuesday 29th, 2019. Gistem Research, a start-up focused on the development of innovative stem cell-derived therapies, will receive an investment of EUR 800.000 from the Caja Rural Bank. This financial support will facilitate the development of its dry eye programme. With the proceeds, Gistem will enter clinical testing, as well as secure a full series A round within this year.
“The funding provided speeds up the ongoing evolvement of a therapeutic approach derived from Human Uterine Cervical Stem Cells, including the technology transfer of the GMP production to our manufacturing partner and preparations for the dry eye phase 1/2 study”, said Fran Vizoso, Gistem´s founder. “We are making good progress in advancing this technology for the treatment of dry eye and other serious diseases for which current therapies are often ineffective. Our goal is to drive vital advancements into clinical practice. This investment allows us to move forward, and we are very pleased to have won the backing of a smart and trustworthy investor”.
GiStem Research (Gijon, Spain) is a privately-owned company developing innovative therapies derived from their proprietary human Uterine Cervical Stem Cells (hUCESCs) platform, a novel source of mesenchymal stem cells showing facile cell isolation protocol, high manufacturing process scalability, and immunoregulatory activity. More information available at: http://www.gistemresearch.com
Phone: +34 984 991 074